Inhibitors of Catechol-O-Methyltransferase

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 324-332

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 13, Iss. 3, 2013-09 ,pp. : 166-194

Bentham Science Publishers

Access to resources Recommend Favorite

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

By Nissinen E.   Kaheinen P.   Penttila K.E.   Kaivola J.   Linden I.-B.  

European Journal of Pharmacology, Vol. 340, Iss. 2, 1997-12 ,pp. : 287-294

Elsevier

Access to resources Recommend Favorite

Entacapone, a catechol-O-methyltransferase inhibitor for treating Parkinson’s disease: review and current status

By Gottwald M.D.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 453-462

Informa Healthcare

Access to resources Recommend Favorite

Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite